-
Mashup Score: 0Court Halt on Trump Cuts for Medical Research Is Extended Nationwide - 5 month(s) ago
The federal order temporarily halts the Trump administration’s plans to slash $4 billion in overhead costs for research at universities and medical centers into diseases like cancer.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Trump's Gag Order Halts CDC Publication - 5 month(s) ago
MMWR did not publish as usual at 1 p.m. today
Source: www.medpagetoday.comCategories: General Medicine News, Hem/OncsTweet-
For the first time in its more than 60-year history, the CDC's Morbidity and Mortality Weekly Report (MMWR) did not go out as scheduled because of a communications pause at federal health agencies https://t.co/3121gHJe2f
-
-
Mashup Score: 16WU Heme Onc Fellowship Program 2024 - 11 month(s) ago
Information about the Washington University in St. Louis Hematology-Oncology Fellowship Training Program
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Want to know more about the Washington University Hem-Onc Fellowship Program @WUHemeOncFellow ? Check out our video below: #MedEd https://t.co/8LkYHngq77 @WashUOnc @WashUHeme @WUSTLmed @WUDeptMedicine @SitemanCenter @BarnesJewish https://t.co/y7fvEFY4bt
-
-
Mashup Score: 2
The Department of Medicine is proud to announce that 146 of our faculty have been selected for the 2024 Castle Connolly Top Doctors® list. The Top Doctors® selection process is entirely merit-based. Doctors cannot pay to be listed. These doctors are best-in-class healthcare providers, embodying excellence in clinical care as well as interpersonal skills. More […]
Source: internalmedicine.wustl.eduCategories: General Medicine News, Hem/OncsTweet-
RT @WashUOnc: 146 @WUDeptMedicine faculty were selected as 2024 Castle Connolly Top Doctors! https://t.co/a6gv0eHagz @WashUAllergyImm @Wash…
-
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
Patrick Hagen Loyola University Medical Center, Maywood, IL Patrick Hagen, Surbhi Sidana, Terri L. Parker, Brian Keith Walker, Antje Hoering, Vaishali Sanchora wala, Jeffrey A. Zonder, Taxiarchis Kourelis, Anita D’Souza, Heather Jolie Landau, Adam Rosenthal, Sikander Ailawadhi, Robert Z Orlowski Loyola University Medical Center, Maywood, IL, Stanford University, Stanford, CA, Yale University, Hamden, CT, Indiana University, Indianapolis, IN, Cancer Research and Biostatistics, Seattle, WA, Boston University
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
@mtmdphd https://t.co/z5sVaPNh4V
-
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
Spencer Lessans Vanderbilt University Medical Center, Nashville, TN Spencer Lessans, Vivek Patel, Bhagirathbhai R. Dholaria, Reena Jayani, Salyka M. Sengsayadeth, Mark Wigger, Amanda Peltier, Sara Horst, Kelly Schlendorf, Rebecca Hung, Stacey Goodman, Bipin N. Savani, Adetola Kassim, Shakthi Bhaskar, Eden Biltibo, Andrew Philip Jallouk, Hasan Siddiqi, Shelton Harrell, Muhamed Baljevic, Lynn Punnoose Vanderbilt University Medical Center, Nashville, TN Background: Systemic AL amyloidosis can lead to
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
Here is my #ASCO24 Top 10 for #Amyloidosis (OK, there are only 2 abstracts total) 1. Long-term outcomes after cardiac transplantation in AL amyloidosis.https://t.co/tlwFgLI9i0 2. Description of upcoming SWOG/Intergroup trial of Dara-CyBorD +/- autotransplant for untreated AL.… https://t.co/3EuF4d0Bja
-
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
Spencer Lessans Vanderbilt University Medical Center, Nashville, TN Spencer Lessans, Vivek Patel, Bhagirathbhai R. Dholaria, Reena Jayani, Salyka M. Sengsayadeth, Mark Wigger, Amanda Peltier, Sara Horst, Kelly Schlendorf, Rebecca Hung, Stacey Goodman, Bipin N. Savani, Adetola Kassim, Shakthi Bhaskar, Eden Biltibo, Andrew Philip Jallouk, Hasan Siddiqi, Shelton Harrell, Muhamed Baljevic, Lynn Punnoose Vanderbilt University Medical Center, Nashville, TN Background: Systemic AL amyloidosis can lead to
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
Here is my #ASCO24 Top 10 for #Amyloidosis (OK, there are only 2 abstracts total) 1. Long-term outcomes after cardiac transplantation in AL amyloidosis.https://t.co/tlwFgLI9i0 2. Description of upcoming SWOG/Intergroup trial of Dara-CyBorD +/- autotransplant for untreated AL.… https://t.co/3EuF4d0Bja
-
-
Mashup Score: 10For Those About to MOC, We Salute You - 1 year(s) ago
If an oncologist participates in a 1-hour multidisciplinary tumor board but does not report it to the American Board of Internal Medicine (ABIM), did it happen? This question vexes me and so many of my colleagues as we try (I believe) to stay on top of the many advances in our field and meet the needs of our patients while also complying with the credentialing requirements of the ABIM. That oncologists and many other clinicians are concerned with the amount of time and money required to maintain credential
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
"For Those About to MOC, We Salute You"--great editorial in @JCO_ASCO And if you have comments/thoughts about @ABIMFoundation MOC in Oncology email your comments to MOC@asco.org @AaronGoodman33 @VincentRK https://t.co/ZDtG6ISzQv https://t.co/AUqLH7j5WX https://t.co/LMX53PNIjw
-
-
Mashup Score: 29
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
Source: www.businesswire.comCategories: General Medicine News, Hem/OncsTweet-
Cilta-cel Carvykti gets FDA approval for second line therapy for myeloma after proteasome inhibitor (PI), and an Imid, refractory to Len! #mmsm #celltherapy #bmtsm @RahulBanerjeeMD @Myeloma_Society @My_Cancer_Haven @DrOlaLandgren @Myeloma_Doc @Rfonsi1 https://t.co/Xnh3pgm9hV
-
-
Mashup Score: 29
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
Source: www.businesswire.comCategories: General Medicine News, Hem/OncsTweet-
Cilta-cel Carvykti gets FDA approval for second line therapy for myeloma after proteasome inhibitor (PI), and an Imid, refractory to Len! #mmsm #celltherapy #bmtsm @RahulBanerjeeMD @Myeloma_Society @My_Cancer_Haven @DrOlaLandgren @Myeloma_Doc @Rfonsi1 https://t.co/Xnh3pgm9hV
-
Court Pause on Cuts to Medical Research Funds Is Expanded Nationwide https://t.co/KcL9SXbfeR